<SEC-DOCUMENT>0001213900-24-090144.txt : 20241024
<SEC-HEADER>0001213900-24-090144.hdr.sgml : 20241024
<ACCEPTANCE-DATETIME>20241024083015
ACCESSION NUMBER:		0001213900-24-090144
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20241024
FILED AS OF DATE:		20241024
DATE AS OF CHANGE:		20241024

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NeuroSense Therapeutics Ltd.
		CENTRAL INDEX KEY:			0001875091
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41084
		FILM NUMBER:		241390815

	BUSINESS ADDRESS:	
		STREET 1:		11 HAMENOFIM ST.
		STREET 2:		BUILDING B
		CITY:			HERZLIYA
		STATE:			L3
		ZIP:			4672562
		BUSINESS PHONE:		972-9-9531142

	MAIL ADDRESS:	
		STREET 1:		11 HAMENOFIM ST.
		STREET 2:		BUILDING B
		CITY:			HERZLIYA
		STATE:			L3
		ZIP:			4672562
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0218521-6k_neurosense.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Report of Foreign Private Issuer<BR>
Pursuant to Rule&nbsp;13a-16 or 15d-16</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Under the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the Month of October 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission File Number: 001-41084</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NeuroSense Therapeutics Ltd.<BR>
</B>(Translation of registrant&rsquo;s name into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NeuroSense Therapeutics Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>11 HaMenofim Street, Building B<BR>
Herzliya 4672562 Israel<BR>
+972-9- 7996183<BR>
</B>(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Indicate by check mark whether the registrant files
or will file annual reports under cover Form&nbsp;20-F or Form&nbsp;40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form&nbsp;20-F&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form&nbsp;40-F&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>INFORMATION CONTAINED
IN THIS REPORT ON FORM 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On October 24, 2024, NeuroSense Therapeutics Ltd.
(the &ldquo;Company&rdquo;) issued a press release entitled &ldquo;New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS
Patients&rdquo;. A copy of the press release is filed herewith as&nbsp;<A HREF="ea021852101ex99-1_neurosense.htm">Exhibit 99.1</A>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This Report on Form 6-K is hereby incorporated
by reference into the registrant&rsquo;s Registration Statements on&nbsp;Form F-3&nbsp;(File No. <A HREF="http://www.sec.gov/Archives/edgar/data/1875091/000121390023003838/ea171892-f3_neurosense.htm">333-269306</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1875091/000121390024030451/ea0203321-posam_neurosense.htm">333-260338</A> ) and&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1875091/000121390022005072/ea154846-s8_neurosense.htm">Form S-8</A>&nbsp;(File No. 333-262480), to be a part thereof from the date on which this report is submitted, to the extent not superseded by
documents or reports subsequently filed or furnished.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>NeuroSense Therapeutics Ltd.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 36%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Date: October 24, 2024</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Alon Ben-Noon</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Alon Ben-Noon</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Office</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea021852101ex99-1_neurosense.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>New Analysis Shows PrimeC Significantly Improves
Key miRNAs in ALS Patients</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Groundbreaking PARADIGM Trial Offers New Hope for ALS Treatment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CAMBRIDGE, Mass., Oct. 24, 2024 /PRNewswire/ --&nbsp;NeuroSense Therapeutics
Ltd. (Nasdaq: NRSN) (&ldquo;NeuroSense&rdquo;), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative
diseases, today announced transformative findings from its PARADIGM clinical trial of PrimeC. These results illuminate a new frontier
in the treatment of ALS (Amyotrophic Lateral Sclerosis), a disease long considered untreatable at its core. The trial demonstrating the
significant impact of PrimeC on the regulation of microRNAs (miRNAs), which play a key role in ALS progression, providing compelling evidence
of the drug&rsquo;s potential to alter the underlying mechanisms of the disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ALS is a fatal disease, known for its relentless destruction of motor
neurons, leading to loss of muscle function, speech, and eventually, the ability to breathe. Understanding the molecular drivers of ALS
is key to finding a way to slow or stop its progression. These findings represent a breakthrough in that understanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Key Findings</B>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Regulation&nbsp;of Critical miRNAs</B>: The
                                                                                       PARADIGM trial revealed that PrimeC regulates specific miRNAs - key genetic markers that control gene expression involved in ALS
                                                                                       progression. These miRNAs were unchanged in the placebo group, underscoring the profound impact of PrimeC on ALS&rsquo;s
                                                                                       pathological pathways. MicroRNAs play a crucial role in regulating how genes express themselves, and their dysregulation has long
                                                                                       been linked to ALS. By restoring balance to these genetic regulators, PrimeC offers a new method of combating this devastating
                                                                                       disease.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Restoring&nbsp;miRNA
Balance in ALS Treatment: </B>PrimeC enhances microRNA (miRNA) maturation, addressing the underlying mechanisms of ALS. By influencing
Dicer, the endonuclease that processes precursor miRNA into active forms, PrimeC may restore the balance of dysregulated miRNAs in ALS
patients. This modulation is thought to facilitate the production of functional miRNAs that regulate gene expression, allowing PrimeC
to target disrupted genetic pathways in ALS and potentially slow disease progression and improve patient outcomes. <B>Clear Differentiation
from Placebo</B>: Patients treated with PrimeC demonstrated consistent effect in miRNA manifestation, with no similar changes seen in
the placebo group. This clear distinction offers compelling evidence of PrimeC&rsquo;s potential as a disease modifying treatment, rather than
a symptomatic one.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>







<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Conclusion:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In conclusion, PrimeC demonstrated beneficial regulation of key miRNAs,
supporting its potential to engage critical genetic targets involved in ALS progression. The 2-fold reduction of several miRNAs following
PrimeC treatment is particularly striking, offering both a powerful biomarker for tracking ALS and a potential pathway for new therapeutic
strategies. This regulation of miRNAs underscores PrimeC&rsquo;s capability to influence ALS at the regulatory level, where previous treatments
have struggled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This work was done in collaboration with Professor Noam Shomron who
is a world-leading scientist in the field of genetics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The results from the PARADIGM trial reflect NeuroSense Therapeutics&rsquo;
dedication to developing treatments that go beyond surface-level symptom management, aiming instead to address the root causes of neurodegenerative
diseases. PrimeC&rsquo;s ability to regulate miRNAs represents an important step toward a future where ALS patients have more therapeutic options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For more information about NeuroSense Therapeutics and its ongoing
research, visit&nbsp;www.neurosense-tx.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About ALS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Amyotrophic lateral sclerosis (&ldquo;ALS&rdquo;) is an incurable neurodegenerative
disease that causes complete paralysis and death within 2-5 years from diagnosis. Every year, more than 5,000 people are diagnosed with
ALS in the U.S. alone, with an annual disease burden of&nbsp;$1 billion. The number of people living with ALS is expected to grow by 24%
by 2040 in the U.S. and EU.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About PARADIGM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PARADIGM is a prospective, multinational, randomized,&nbsp;double-blind,
placebo-controlled Phase 2b (NCT05357950) clinical trial of PrimeC in ALS. The trial included 68 participants living with ALS in Canada,
Italy, and Israel. 96% of the trial participants who completed the 6-month double-blind portion of the trial chose to receive treatment
with PrimeC through a 12-month open label extension. Furthermore, to date (June 2024) all participants that completed the 18-month trial
treatment duration, requested to continue PrimeC, which is provided to them in an Investigator Initiated Trial, not limited with time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As previously reported, in the 6-month double-blind segment of the
trial, the data showed clinically meaningful signs of efficacy with a 29% difference in favor of PrimeC vs placebo in analysis of the
intent to treat (ITT) population. In the PP top-line analysis&nbsp;from PARADIGM, a statistically significant slowing of disease progression
was observed with a 37.4% (p=0.03) difference in ALSFRS-R in favor of PrimeC vs placebo. Most patients enrolled in both the active and
placebo arms of the trial were concurrently treated with Riluzole, the ALS standard of care medication, indicating PrimeC slowed disease
progression well beyond the level afforded by the FDA approved ALS drug.&nbsp; &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About PrimeC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PrimeC, NeuroSense&rsquo;s lead drug candidate, is a novel extended-release
oral formulation composed of a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib. PrimeC is designed
to synergistically target several key mechanisms of ALS that contribute to motor neuron degeneration, inflammation, iron accumulation
and impaired ribonucleic acid (&ldquo;RNA&rdquo;) regulation to potentially inhibit the progression of ALS. NeuroSense completed a Phase
2a clinical trial which met its safety and efficacy endpoints including reducing functional and respiratory deterioration and statistically
significant changes in ALS-related biological markers indicating PrimeC&rsquo;s biological activity. PrimeC was granted Orphan Drug Designation
by the U.S. Food and Drug Administration and the European Medicines Agency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About NeuroSense</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company
focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes
that these diseases, which include amyotrophic lateral sclerosis&nbsp;(ALS), Alzheimer&rsquo;s disease and Parkinson&rsquo;s disease, among others,
represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients
to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers,
NeuroSense&rsquo;s strategy is to develop combined therapies targeting multiple pathways associated with these diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For additional information, we invite you to visit our&nbsp;website&nbsp;and
follow us on&nbsp;LinkedIn, YouTube&nbsp;and&nbsp;X. Information that may be important to investors may be routinely posted on our website
and these social media channels.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This press release contains &ldquo;forward-looking statements&rdquo;
that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press
release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words
such as &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;contemplate,&rdquo; &ldquo;could,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo;
&ldquo;intend,&rdquo; &ldquo;seek,&rdquo; &ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;plan,&rdquo; &ldquo;potential,&rdquo; &ldquo;predict,&rdquo;
&ldquo;project,&rdquo; &ldquo;target,&rdquo; &ldquo;aim,&rdquo; &ldquo;should,&rdquo; &ldquo;will&rdquo; &ldquo;would,&rdquo; or the negative of these
words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based
on NeuroSense Therapeutics&rsquo; current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to
predict and include statements regarding Prime C&rsquo;s potential to treat ALS. Further, certain forward-looking statements are based on assumptions
as to future events that may not prove to be accurate. The future events and trends may not occur and actual results could differ materially
and adversely from those anticipated or implied in the forward looking statements. These risks include the risk of a delay in submission
by the Company of its regulatory dossier,&nbsp;that regulatory approvals for PrimeC will be delayed or not obtained in Canada or elsewhere;
that the market opportunity in Canada will not be as currently estimated; unexpected R&amp;D costs or operating expenses, insufficient
capital to complete development of PrimeC, a delay in the reporting of additional results from PARADIGM clinical trial, the timing of
expected regulatory and business milestones, risks associated with meeting with the FDA and Health Canada to determine the best path forward
following the results from PARADIGM clinical trial, including a delay in any such meeting; the potential for PrimeC to safely and effectively
target ALS; preclinical and clinical data for PrimeC; the uncertainty regarding outcomes and the timing of current and future clinical
trials; timing for reporting data; the development and commercial potential of any product candidates of Neurosense; the ability of NeuroSense
to remain listed on Nasdaq; and other risks and uncertainties set forth in NeuroSense&rsquo;s filings with the Securities and Exchange Commission
(SEC). You should not rely on these statements as representing our views in the future. More information about the risks and uncertainties
affecting NeuroSense is contained under the heading &ldquo;Risk Factors&rdquo; in the Annual Report on Form 20-F filed with the Securities
and Exchange Commission on April 4, 2024 and NeuroSense&rsquo;s subsequent filings with the SEC. Forward-looking statements contained in this
announcement are made as of this date, and NeuroSense undertakes no duty to update such information except as required under applicable
law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Logo: https://mma.prnewswire.com/media/1707291/4985814/NeuroSense_Therapeutics_Logo.jpg</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For further information: Email:&nbsp;info@neurosense-tx.com, Tel: +972
(0)9 799 6183&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !> 5$# 2(  A$! Q$!_\0
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M)"KLRP=V PF3&%Y/0L3@ ?>.!UQ5NLZ_)4Q,0SHJ2L8DR6D8-#LPHR6VDDG
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MBZ3XG^)OBATGN;O4O#6GZ;I][IX\-DV5P=,U,:3HVFW=O<)/;2ZF@<V7O4?
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M)1J?681JQIMUHPN[M0?Y ?"O_@C1^S7X#N-,UCQ?KWQ$\?Z_8,DJ7$GB?5O
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MH?NYO()4F0L#S_@[_@FW^T2/VI?!O[47Q/\ C[\/_&'B/1/%WA_Q#X@GTWP
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M&7PR_,<,L]PD,AJT\5_9V(J8"E1Q:HMSJ2EA*V):=+EBW)\DORKM_"/[?/\
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M5:=2I"#FX\ DKRR6T^H)+/#&C6]PT.]TCCC8F/\ >+E?M \JV@D7(:.26)"
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MSQJC30G:@9HU(9@P#J0!&^<KD8(#?D/I_P#P54@UCX&:E^TOH_[('[1M_P#
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MNT%M/M53@+(TI@>0'/1=^W!SM##?N6=C!9*(H(1#&%14C5$CB4(6P(XDFE5
M"QW86/(V_>Q\MV65(QO<HJ*K$RN0JJJ+O8LQ(55559F)( "ECP"0UWA)):=%
MVE V74 >:0L8)SP7) C[L6&W)-7*4MY<S35FU[U[JR^&-]VKW;[N]KG+1RW*
M,-5EB,!E>%HXIRYJU3EA!SDW:3<GR\SLWK>5]W=I,9-$TP".@*$$-A8R<''7
M?G;W^ZK9[@8%<O>^#="N9XI[O2[:[FBW_9IOLUC+/!O*&41FXLMD:RA(PYR=
MPC7.-H)[!?+P"KE@PRN"&#;@6!7!R00"P('W03T!J*<(Y0DNF V" 2"&V<\
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MV#RS"4Z\Y-UW>G%U)2^)W;]^[;=]?6^U'^SX)&<RVZY9M^?GD)W=028H<!<
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MH;F2>"PCM[A]AEN%A1)I<!]H\V.S"@IN8?))_%R>>>FE>/8[&9$1 2[%U"H
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M2$;>3.KV]RL:?OHHU5C$$A@C2/RH$=I8H93$QBTZ/?+$Q<S*IFC5?Q(^!_\
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M]'>Z0HP)&TJ [')&,Y=SD?WOE"\CUP:L*""WN<C]:8&RP/;H!]?\C-2YYQ[
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E*#4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
